Loading stock data…
BLFS
$21.21+0.13 (+0.62%)
Market ClosedLast close May 1
BioLife Solutions, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioLife Solutions, Inc. in the Healthcare sector is trading at $21.21. The stock is currently 28% below its 52-week high of $29.62, remaining 10.8% below its 200-day moving average. Technical signals show neutral RSI of 57 and bearish MACD signal, explaining why BLFS maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 57) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$21.21
Potential Upside
5%
Whystock Fair Value$22.27
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$32.40+52.8%
Range$30.00 – $34.00
Fundamentals
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.10B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.00
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.98%
Volume
Today's trading volume
166,569
Recent News
Zacks Industry Outlook Highlights Phibro Animal Health, BioLife Solutions, Omeros and Brainsway
Medical Products stocks face tariff and cost pressures, but Phibro Animal Health and peers leverage innovation, AI and demand trends to drive growth.
4 Medical Product Stocks to Buy From a Challenging Industry
The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.
Discover BioLife Solutions And 2 Other Stocks That May Be Priced Below Their Estimated Value
Over the last 7 days, the United States market has risen by 1.7%, contributing to a remarkable 34% increase over the past year, with earnings anticipated to grow by 16% annually in the coming years. In such a thriving environment, identifying stocks that may be priced below their estimated value can present compelling opportunities for investors seeking potential growth and value.
Utah Medical Gains 32% in a Year: Should You Buy the Stock?
UTMD's niche leadership, global footprint, and strong cash generation position it to benefit from rising demand for high-quality maternal and neonatal healthcare solutions.
April 2026's Stocks Estimated To Be Below Fair Value
The United States market has recently experienced a robust climb, with a 4.4% increase in the last week and an impressive 32% rise over the past year, while earnings are projected to grow by 16% annually. In this context of strong market performance, identifying stocks that are estimated to be below their fair value can present opportunities for investors seeking potential growth at reasonable prices.